Monoclonal antibody · Inhibitor of coagulation factor XI (F11) · developed by REGENERON PHARMACEUTICALS
Cenvacibart is an IgG4 human monoclonal antibody that binds the catalytic domain of coagulation factor XI, preventing its activation to FXIa. This inhibits contact activation-initiated blood coagulation and thrombus formation. It is being studied in venous thromboembolism.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07318610 | Phase 3 | Peripheral Artery Disease (PAD) | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Venous Thromboembolism (VTE)
Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →